Marker Therapeutics, Inc. (NASDAQ:MRKR – Get Free Report) shares crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $1.31 and traded as high as $1.68. Marker Therapeutics shares last traded at $1.32, with a volume of 35,846,329 shares changing hands.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on MRKR. Weiss Ratings lowered Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, November 13th. HC Wainwright reiterated a “buy” rating on shares of Marker Therapeutics in a research report on Friday, August 21st. Finally, Zacks Research downgraded Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 13th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Marker Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $10.00.
Check Out Our Latest Stock Report on Marker Therapeutics
Marker Therapeutics Stock Performance
Marker Therapeutics (NASDAQ:MRKR – Get Free Report) last announced its quarterly earnings results on Monday, November 16th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. The business had revenue of $1.29 million during the quarter, compared to the consensus estimate of $2.12 million. Equities analysts forecast that Marker Therapeutics, Inc. will post -0.64 EPS for the current fiscal year.
Institutional Investors Weigh In On Marker Therapeutics
A hedge fund recently bought a new stake in Marker Therapeutics stock. Concurrent Investment Advisors LLC bought a new stake in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 67,963 shares of the company’s stock, valued at approximately $100,000. Concurrent Investment Advisors LLC owned 0.41% of Marker Therapeutics at the end of the most recent quarter. 22.39% of the stock is currently owned by institutional investors.
Marker Therapeutics Company Profile
Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen. The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies.
Recommended Stories
- Five stocks we like better than Marker Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
